MedTrace Logo

A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects

NCT02760758 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2021-04-20

No results posted yet for this study

Summary

This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals

Conditions

  • Hepatitis C

Interventions

DRUG

CDI-31244

NNI

DRUG

Placebo

no active ingredients

Sponsors & Collaborators

  • Cocrystal Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Judy Pattassery · Cocrystal Pharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-03-31
Completion
2017-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02760758 on ClinicalTrials.gov